Cancer League of Colorado Clinical Trials Funded

Beginning during the fiscal year 2015-2016 Cancer League of Colorado’s Board of Directors approved funding of Investigator Initiated Clinical Trials. As of June 30, 2019 the following Trials have been funded:

Click Here to Download as .pdf

  2015 to June 30, 2019  
  Investigator-Initiated Clinical Trial Grants  
Karyn Goodman, MD A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) after Induction Chemotherapy for Locally Advanced Pancreatic Cancer   $50,000
Paul Maroni, MD A Phase 2 Study of Grape Seed Extract (GSE) Product I Asymptomatic Non-Metastatic Prostate Cancer Patients with Rising PSA           $50,000
Dan Pollyea MD and Clay Smith MD Phase I Trial of Arsenic Trioxide with Cyclophosphamide in Patients with Relapsed/Refractory AML (Acute Myloid Leukemia)           $50,000
S. Lindsey Davis MD Identifying biomarkers of immune-related toxicity in cancer patients treated with immune checkpoint inhibitors; a pilot study           $50,000
Elissa Kolva, PhD Effect of Guided Imagery for Radiotherapy-Related Distress           $50,000
Elizabeth Kessler, MD Bipolar Testosterone Therapy in Prostate Cancer           $70,000
Jennifer Diamond, MD & Christine Fisher, MD, MPH A Phase 1b Study of Radiation and Anti-PD-1 Therapy in Recurrent Women’s Cancers  $100,000
Drs. Olsen, Leal & Goodman  Pilot Study of Induction FLOT Followed by Neoadjuvant Chemoradiation in Patients With Resectable Adenocarcinoma of the Esophagus or Gastroesophageal Junction   $50,000
Breelyn A. Wilky, MD An Open Label, Phase II Efficacy Trial of Doxorubicin and Olaratumab in Combination With Dual Checkpoint Blockade Using agen1884 And agen2034 for Advanced or Metastatic Soft Tissue Sarcomas $100,000
Kelly Faulk, MD Evaluate the Safety and Tolerability and Define the Maximum Tolerated dose (MTD) of Losaratan in Combination with Sunitinib in Pediatric and Young Adult Patients with Relapsed or Refractory Osteosarcoma  $50,000
Rao Mushtaq, MD; Ross Camidge, PhD; Rustain Morgan, MD; Micol Rothman, MD Study Relating to Exploring the Potential Differential Need for Anti-resorptive Bone Medications (Bisphosphonates or RANK-L Inhibitors) in Patients with Advanced Non-Small Cell Lung Cancer and Bone Metastases With and Without Actionable Driver Mutations          $50,000